{"title":"[Hemorheologic effects of hydroxyethyl starch 200/0.5, dextran 40, oxypolygelatine and full electrolyte solution over 48 hours].","authors":"S Brehme, G Keysser, A Turowski, H H Schmidt","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>Four patient groups (n = 28 patients) received in a randomised clinical trial a single intravenous infusion of 500 ml of 10% dextran 40, 3.5% oxypolygelatine, 6% hydroxyethyl starch 200/0.5 or saline solution, respectively. The haemorheological parameters haematocrit, plasma viscosity and erythrocyte aggregation were followed up during 48 hours. In our study oxypolygelatine showed better rheological results than HAES 200/0.5. Dextran 40 especially increased the plasma viscosity and erythrocyte aggregation, so that we cannot recommend this plasma substituent for hypervolemic haemodilution.</p>","PeriodicalId":23901,"journal":{"name":"Zeitschrift fur die gesamte innere Medizin und ihre Grenzgebiete","volume":"48 10","pages":"506-10"},"PeriodicalIF":0.0000,"publicationDate":"1993-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Zeitschrift fur die gesamte innere Medizin und ihre Grenzgebiete","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Four patient groups (n = 28 patients) received in a randomised clinical trial a single intravenous infusion of 500 ml of 10% dextran 40, 3.5% oxypolygelatine, 6% hydroxyethyl starch 200/0.5 or saline solution, respectively. The haemorheological parameters haematocrit, plasma viscosity and erythrocyte aggregation were followed up during 48 hours. In our study oxypolygelatine showed better rheological results than HAES 200/0.5. Dextran 40 especially increased the plasma viscosity and erythrocyte aggregation, so that we cannot recommend this plasma substituent for hypervolemic haemodilution.